ACADIA PHARMACEUTICALS INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $391.0M | $226.5M | $-61.3M | $-216.0M | $-167.9M | $-281.6M | $-235.3M | $-245.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $871.0K | $920.0K | $1.5M | $2.0M | $2.2M | $1.5M | $1.3M | $1.5M |
| Amortization | $10.9M | $15.0M | $4.1M | $0 | $1.1M | $1.5M | $1.5M | $1.5M |
| Stock-Based Compensation | $52.1M | $67.0M | $66.4M | $68.2M | $63.6M | $84.4M | $82.3M | $81.6M |
| Net Cash from Operating Activities | $109.8M | $157.7M | $16.7M | $-114.0M | $-125.7M | $-136.2M | $-151.1M | $-167.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $4.7M | $523.0K | $50.0K | $0 | $1.1M | $7.6M | $1.1M | $2.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-302.6M | $-30.5M | $32.0M | $73.2M | $-71.1M | $192.5M | $-165.8M | $-71.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $49.9M | $6.8M | $25.1M | $8.2M | $18.2M | $81.0M | $371.8M | $306.6M |
| Net Change in Cash | $-142.8M | $133.9M | $73.8M | $-32.6M | $-178.6M | $137.3M | $54.9M | $67.7M |
| Free Cash Flow | $105.1M | $157.2M | $16.7M | $-114.0M | $-126.8M | $-143.8M | $-152.3M | $-169.6M |